Abstract: The present invention relates to a lysosomal protein composition comprising a plurality of lysosomal proteins that are potentially diversely glycosylated according to a glycosylation pattern, wherein said glycosylation pattern has at least 45% paucimannosidic N-glycans; a method of manufacturing the lysosomal protein composition in a bryophyte plant or cell, and medical and non-medical uses of the lysosomal protein composition. E.g. the lysosomal protein can be ?-Galactosidase for the treatment of Fabry Disease or ?-Glucoceramidase for the treatment of Gaucher's Disease. The unique glycosylation results in improved therapeutic efficacy—surprisingly even without mannose-6-phosphate that is common for CHO cell produced lysosomal proteins.

Abstract: Provided are mutant polymerases having DNA polymerase activity and reverse transcriptase activity or strand displacement activity, along with target nucleic acid amplification methods employing such mutant polymerases.

Abstract: An object of the present invention is to provide a microorganism that efficiently produces a PUFA and a method for producing a PUFA using the microorganism. The present invention relates to a microorganism capable of producing a polyunsaturated fatty acid (PUFA), in which a gene encoding an exogenous polyketide synthase dehydratase (PS-DH) domain having a higher activity against 3-hydroxyhexanoyl acyl carrier protein (3-hydroxyhexanoyl ACP) than an endogenous FabA-like ?-hydroxyacyl-ACP dehydratase (FabA-DH) domain has been introduced into a microorganism having a PUFA metabolic pathway, and the like.

Abstract: Provided is an inexpensive and efficient microbiological method for producing a protein. The method for producing a protein comprises culturing a microorganism in the presence of glycosylamine.

Abstract: The present disclosure provides AcrIIA7 polypeptides, nucleic acids encoding the AcrIIA7 polypeptides, and kits comprising the AcrIIA7 polypeptides and/or nucleic acids encoding the ACRIIA7 polypeptides. The present disclosure provides methods of inhibiting an activity of a Cas9 polypeptide.

Abstract: Processes for producing reduced coenzyme Q10 (CoQ10) are provided. The processes may include preparing a reaction mixture, which includes oxidized CoQ10, a reductase, a supplement coenzyme, a coenzyme regeneration enzyme, and a substrate of the coenzyme regeneration enzyme, and providing a condition so that components of the reaction mixture react to produce the reduced CoQ10.

Abstract: The disclosure relates to the field of specialty chemicals and methods for their synthesis. In embodiments, the disclosure provides viable bacterial cells which comprise heterologous dual 3-hydroxy-acyl-ACP dehydratase/isomerases, etc. The disclosure further provides monounsaturated fatty acid derivative molecules produced by the viable bacterial cells which are non-native to the bacterial cells. The disclosure further provides methods for the preparation and production of non-native monounsaturated fatty acid derivative molecules such as e.g., an ?3-monounsaturated fatty acid derivative, an ?5-monounsaturated fatty acid derivative, an ?9-monounsaturated fatty acid derivative, an ?11-monounsaturated fatty acid fatty acid derivative, etc.

Abstract: The present disclosure provides compositions, methods, kits, systems and apparatus that are useful for nucleic acid polymerization. In particular, modified polymerases and biologically active fragments thereof, such as modified Taq polymerases, are provided that allow for improved nucleic acid amplification. In some aspects, the disclosure provides modified polymerases having improved thermostability, accuracy, processivity and/or read length as compared to a referenceTaq polymerase. In some aspects, the disclosure relates to modified polymerases or biologically active fragments thereof, useful for amplification methods, and in practically illustrative embodiments, emulsion PCR.

Abstract: Provided in the present invention is a phospholipase C mutant with high enzyme activity, a polypeptide with the sequence as shown in SEQ ID NO:7, or a polypeptide derived from the phospholipase C formed by performing substitution, deletion or addition of one or a plurality of amino acids on the polypeptide of SEQ ID NO:7 while retaining the phospholipase C activity provided by SEQ ID NO:7. The phospholipase C mutant of the present invention can improve degumming efficiency and increase the yield of diacylglycerol (DAG) during degumming.

Abstract: Methods and compositions are described for selecting and identifying orthogonal aminoacyl synthetase-tRNA pairs and their use to incorporate unnatural amino acids in a site-specific manner in proteins. Specifically described is a novel E. coli tyrptophanyl synthetase-tRNA pair that functions as both an opal and amber suppressor and that incorporates tryptophan analogs into proteins.

Abstract: The present invention provides an isolated peptide of SEQ ID NO: 1 needed for primase active as well as new replicative DNA polymerase enzymes, preferably that of SEQ ID NO: 2, comprising said peptide. Thus, these DNA polymerases are endowed with priming activity and do not require externally provided primers for initiating and performing DNA amplification. These polymerases are able to carry out a faithful and processive de novo DNA synthesis of DNA templates in the absence of pre-synthetized primers. Therefore, these enzymes of the invention act both as primases and DNA polymerases. Furthermore, they show translesion synthesis capacity, so that they may be useful not only for whole-genome amplification but also for the amplification of damaged DNAs. The invention further refers to methods for amplifying templates DNAs using these enzymes.

Abstract: The invention relates to subtilase variants and detergent compositions comprising the variants, as well as methods of producing the variants and methods for stabilizing a subtilase variant.

Abstract: The present disclosure relates, according to some embodiments, to compositions and analysis of RNA (e.g., dephosphorylated oligoribonucleotides) including, for example, natural and/or synthetic RNAs. A composition may comprise, for example, an endoribonuclease having an amino acid sequence that (i) corresponds to an amino acid sequence of a first species (e.g., Homo sapiens, Escherichia coli, Aspergillus oryzae, Momordica charantia, Pyrococcus furiosus, Cucumis sativus, and Sus scrofa) or (ii) is a non-naturally occurring sequence; and/or an RNA end repair enzyme having an amino acid sequence that (i) corresponds to an amino acid sequence of a species other than the first species (e.g., a bacterial species or a bacteriophage species) or (ii) is a non-naturally occurring sequence.

Abstract: This invention relates to recombinant nucleic constructs comprising a sequence-specific DNA binding protein, DNA-dependent DNA polymerase and a DNA encoded repair template, optionally a DNA endonuclease or wherein the sequence-specific DNA binding protein comprises DNA endonuclease activity, and methods of use thereof for modifying nucleic acids in cells and organisms.

Abstract: The present invention provides high efficiency targeted and marker-less single, double, triple, quadruple, and quintuple integrations by using CRISPR in host cells, including Pichia.

Abstract: Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein.

Abstract: Provided herein are engineered variants of archaeal polymerases that exhibit exonuclease-minus activity, enhanced thermostability, enhanced incorporation of 3? modified nucleotides, improved uracil-tolerance and/or reduce sequence-specific errors in polymerase-catalyzed nucleotide binding and extension reactions relative to wild type polymerase enzymes. Also provided are uses of the engineered polymerases for forming complexed polymerases and forming binding complexes, and uses for conducting nucleic acid sequencing reactions.

Abstract: The disclosure relates to a Type II CRISPR/Cas9 genome editing system, belonging to the technical field of genome editing. The genome editing system comprises a Cas9 protein, helper proteins, a CRISPR RNA and a trans-activated CRISPR RNA; wherein the Cas9 protein is a DNA endonuclease, and the Cas9 protein has an amino acid sequence as shown in SEQ ID NO: 1, or an amino acid sequence with at least 80%, 85%, 90%, 95%, 98%, or 99% homology to the amino acid sequence as shown in SEQ ID NO: 1. According to the disclosure, through bioinformatics analysis, the Type II CRSIPR/Cas9 genome editing system in the Faecalibaculum rodentium is discovered, and the genome editing system is applied to editing prokaryotic or eukaryotic genes and provides a new selection for a genome editing toolbox.

Abstract: The invention relates to a process for producing a fermentation broth by culturing a microorganism.

Abstract: Novel engineered non-natural deaminases are provided. Methods and compositions are provided for modifying the genome of a cell, including a plant cell. Genome modification through guided CRISPR polypeptides and multiple deaminases are provided. Engineered non-natural novel deaminases, including adenosine deaminases are provided. These novel deaminases have improved activity in cells including plant cells.